No Dual Antiplatelet Therapy in Atrial Fibrillation

Antonio L Aguilar-Shea
Centro de Salud Puerta de Madrid, Spain

*Corresponding author: Antonio L Aguilar-Shea, Centro de Salud Puerta de Madrid, Avda. del Ejército 61, 28802 Alcalá de Henares (Madrid), Spain, Tel: +34918806699; Fax: +34918823392; E-mail: antonio.aguilar@salud.madrid.org

Citation: Aguilar-Shea AL (2016) Double High Risk Atrial Fibrillation Patient’s. Arrhythm Open Access 1: e103. doi:10.4172/atoa.1000e103

Received date: April 15, 2016; Accepted date: April 15, 2016; Published date: April 19, 2016

Copyright: © Aguilar-Shea AL. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Editorial

Managing atrial fibrillation is common in daily practice and an important part of this management is deciding over the embolism prevention strategy. Oral anticoagulants (warfarin, acenocumarol, apixaban, rivaroxaban or dabigatran) and antiplatelets (acetylsalicylic acid or clopidogrel) are the two groups of drugs used to prevent embolism events. To choose wisely CHA$_2$DS$_2$-VASC embolism risk scale aids in making this decision. But, is dual antiplatelet therapy, acetylsalicylic acid plus clopidogrel, a correct option in embolism prevention in atrial fibrillation?

A primary source search was done in Pubmed (Medline) using as key words “dual antiplatelet therapy and atrial fibrillation” and the most relevant articles were chosen [1-4]. Secondary sources guidelines were also reviewed, but only two major guidelines discussed this matter, European Society of Cardiology [5] and Uptodate [6]. The conclusion was that double anticoagulation was not an appropriate treatment for embolism prevention in atrial fibrillation. The risk of bleeding of dual antiplatelet therapy was similar to the anticoagulation therapy but the embolism prevention was much lower.

References